ホーム › 間質性肺疾患 › ペンシルベニア › Philadelphia
Philadelphia、PAにおける間質性肺疾患の臨床試験
Philadelphiaとその周辺地域（約30マイル以内）の拠点で、間質性肺疾患に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
被験者募集中第3相
- University of Pennsylvania, Philadelphia
- Temple University, Philadelphia
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
被験者募集中第3相
- University of Pennsylvania, Philadelphia
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
被験者募集中第2相
- Thomas Jefferson University, Philadelphia
- Temple Lung Center, Temple University, Philadelphia
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
被験者募集中第3相
- USA013, Philadelphia
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
被験者募集中第3相
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
被験者募集中第3相
- GSK Investigational Site, Philadelphia
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
被験者募集中第2/3相
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
被験者募集中
- Thomas Jefferson University, Philadelphia
- Temple University of The Commonwealth System of Higher Education, Philadelphia
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
被験者募集中観察研究
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University - Sidney Kimmel Medical College, Philadelphia
- Temple Lung Center, Philadelphia
- 他1件
Platform Clinical Study for Conquering Scleroderma
被験者募集中第2相
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
被験者募集中観察研究
- Temple University, Philadelphia
- Thomas Jefferson University, Philadelphia
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
被験者募集中第2相
- Temple University, Philadelphia
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
被験者募集中第3相
- Hospital of the University of Pennsylvania, Philadelphia
- Jefferson Honickman Center, Philadelphia
- Temple University Hospital, Philadelphia
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
被験者募集中観察研究
- Children's Hospital of Philadelphia, Philadelphia
Feasibility of Semaglutide in Advanced Lung Disease
被験者募集中第1/2相
- University of Pennsylvania Perelman School of Medicine, Philadelphia
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
被験者募集中第2相
- Temple University Hospital-Temple Lung Center, Philadelphia
他の都市における間質性肺疾患の試験
- New York City, NY18件の研究
- Los Angeles, CA14件の研究
- Charleston, SC13件の研究
- Kansas City, KS13件の研究
- Durham, NC13件の研究
- Chicago, IL12件の研究
- Houston, TX12件の研究
- Aurora, CO11件の研究
- Ann Arbor, MI11件の研究
- Salt Lake City, UT9件の研究
- Dallas, TX9件の研究
- Boston, MA9件の研究
Philadelphiaにおける他の研究
- がん（全種類）59件の研究
- 乳がん56件の研究
- 非小細胞肺癌51件の研究
- 転移性癌46件の研究
- 前立腺がん44件の研究
- 大腸癌44件の研究
- 卵巣がん44件の研究
- 肺がん36件の研究
- 急性骨髄性白血病34件の研究
- 心不全31件の研究
- 子宮内膜がん28件の研究
- うつ病26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。